Alpha Hc. - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

tadalafil alphapharm tadalafil 10mg film-coated tablets blister pack

alphapharm pty ltd - tadalafil, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; sodium lauryl sulfate; colloidal anhydrous silica; povidone; poloxamer; lactose; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

alphamox 500 capsule bottle

alphapharm pty ltd - amoxicillin trihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphamox 250 capsule bottle

alphapharm pty ltd - amoxicillin trihydrate -

India - English - Central Drugs Standard Control Organization

alpha cad 10 tab

shrrishti hc. - alpha lipioic acid - tab - with multivitamin,multimineral - 10

United States - English - NLM (National Library of Medicine)

anti age skin- alpha-tocopherol - ascophyllum nodosum - botryoglossum platycarpum - fucus serratus - fucus vesiculosus - isoleuc

guna spa - alpha-tocopherol (unii: h4n855pnz1) (alpha-tocopherol - unii:h4n855pnz1), laminaria digitata (unii: 15e7c67ee8) (laminaria digitata - unii:15e7c67ee8), botryoglossum platycarpum (unii: pta4328m4z) (botryoglossum platycarpum - unii:pta4328m4z), fucus serratus (unii: v8k40wnw5b) (fucus serratus - unii:v8k40wnw5b), sus scrofa capillary tissue (unii: 253a0356pn) (sus scrofa capillary tissue - unii:253a0356pn), ubidecarenone (unii: ej27x76m46) (ubidecarenone - unii:ej27x76m46), sus scrofa collagen (unii: i - alpha-tocopherol 4 [hp_c] in 4 g - alpha tocopherol 4c antioxidant brown algae, laminaria 4c detoxification and drainage brown algae, platycarpus 4c detoxification and drainage brown algae, serratus 4c detoxification and drainage capillary tissue 4c blood flow support coenzyme q-10 4c antioxidant collagen 4c eutrophic action fucus vesiculosus 4c detoxification isoleucine 4c dermis protein metabolic support knotted wrack 4c skin tone support leucine 4c dermis protein metabolic support placenta totalis 4c vascular stimulation retinol 4c antioxidant sea lettuce 4c skin tone selenium metallicum 4c cell metabolic support skin tissue 4c eutrophic supp

United States - English - NLM (National Library of Medicine)

zemaira- alpha-1-proteinase inhibitor human kit zemaira- .alpha.1-proteinase inhibitor human kit

csl behring llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - zemaira is an alpha1 -proteinase inhibitor (a1 -pi) indicated for chronic augmentation and maintenance therapy in adults with a1 -pi deficiency and clinical evidence of emphysema. zemaira increases antigenic and functional (anti-neutrophil elastase capacity [anec]) serum levels and lung epithelial lining fluid (elf) levels of a1 -pi. clinical data demonstrating the long-term effects of chronic augmentation therapy of individuals with zemaira are not available. the effect of augmentation therapy with zemaira or any a1 -pi product on pulmonary exacerbations and on the progression of emphysema in a1 -pi deficiency has not been demonstrated in randomized, controlled clinical studies. zemaira is not indicated as therapy for lung disease patients in whom severe a1 -pi deficiency has not been established. - zemaira is contraindicated in patients with a history of anaphylaxis or severe systemic reactions to zemaira or a1 -pi protein. - zemaira is contraindicated in immunoglobulin a (iga)-deficient patients with antibodies against iga, due to the risk of severe hypersensitivity [see warnings and precautions (5.2)] . risk summary no animal reproduction studies have been conducted with zemaira and its safety for use in human pregnancy has not been established in controlled clinical trials. since alpha1 -proteinase inhibitor is an endogenous human protein, it is considered unlikely that zemaira will cause harm to the fetus when given at recommended doses. however, zemaira should be given with caution to pregnant women. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the excretion of zemaira in human milk, the effect on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for zemaira and any potential adverse effects on the breastfed infant from zemaira or from the underlying maternal condition. safety and effectiveness in the pediatric population have not been established. the safety and efficacy of zemaira in the geriatric population have not been established due to an insufficient number of subjects.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

accensi alpha-cypermethrin pc50 residual insecticide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

alpha-cypermethrin

aimco kr australia pty ltd - alpha-cypermethrin - unknown - alpha-cypermethrin pyrethroid active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

alpha-cypermethrin

sinon australia pty limited - alpha-cypermethrin - unknown - alpha-cypermethrin pyrethroid active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

acp alphacyp 100 insecticide